As we approach
the 40 year anniversary
of Dr. Northway's
seminal 1967 report
(1), bronchopulmonary
dysplasia (BPD)
remains a constant
concern in the
Neonatal Intensive
Care Unit (NICU).
Despite an evolution
in describing
the pathologic
appearance of
BPD, the long-reported
abnormalities
remain: influx
of alveolar macrophages
and neutrophils,
and later lymphocytes;
cellular injury
in particular
to type I cells
and endothelial
cells; type II
cell hyperplasia;
alveolar fibrosis;
impaired alveolar
development; and
impaired vascular
development. Also,
over the past
decades, there
has been a change
in the patient
population most
likely to be affected
by this disease:
it is now more
commonly seen
in very premature,
extremely low
birth weight infants
(<1000 grams)
and rarely seen
in infants born
at term. Despite
both the marked
increase in survival
of extremely premature
infants and ongoing
advances in neonatal
technology and
management, BPD
is still common
and takes a toll
in both mortality
and morbidity.
With BPD affecting
as many as 25,000
U.S. infants each
year and
with estimated
overall costs
second only to
those for treating
asthma and far
exceeding the
costs of treating
cystic fibrosis
(Division of Lung
Diseases and Office
of Prevention,
Education, and
Control, November
1998) it
has become clear
that BPD is itself
an independent
risk factor for
poor neurodevelopmental
outcome. The concept
that the exposure
of the lung at
such an early
stage of development
to becoming the
organ of gas exchange
is fundamental
to the pathogenesis
of BPD and has
long been a focus
of study, including,
in recent years,
a strong concentration
on understanding
the arrest of
alveolar development
and abnormal vasculature.
The molecular
basis of lung
development itself
has been the subject
of extensive research
to define and
comprehend the
mechanisms of
changes in the
alveolarization
and vascularization
seen in BPD.
In this issue
we focus on the
contributions
of inflammation,
the development
of the vasculature
and alveolarization,
and genetic
predispositions
to the pathogenesis
of BPD.
Commentary,
Figure and
Reviews: Rita M. Ryan, MD
Chief, Division of
Neonatology
State University of
New York at Buffalo,
Women and Children's
Hospital of Buffalo,
Buffalo, New York
Reviews: Ibrahim S. I. Mohamed, MD
Fellow, Division of
Neonatology
State University of
New York at Buffalo,
Women and Children's
Hospital of Buffalo,
Buffalo, New York
Guest
Faculty Disclosure Rita
M. Ryan, MD
Faculty
Disclosure:
No relationship
with commercial
supporters.
Ibrahim
S. I. Mohamed,
MD
Faculty
Disclosure:
No relationship
with commercial
supporters.
Unlabelled/Unapproved
Uses:
No
faculty member
has indicated
that their presentation
will include
information
on off label
products.
Edward
E, Lawson, M.D.
Professor
Department of
Pediatrics —
Neonatalogy
The Johns Hopkins
University School
of Medicine
Lawrence
M. Nogee, M.D.
Associate
Professor
Department of
Pediatrics —
Neonatalogy
The Johns Hopkins
University School
of Medicine
Christoph U. Lehmann, M.D.
Assistant Professor
Department of Pediatrics, Health Information
Science and Dermatology
The Johns Hopkins University School of Medicine
Lorraine
A. Harbold,
R.N., M.S.
The
Johns Hopkins
Hospital
NICU Education
Coordinator
The
Johns Hopkins
University School
of Medicine
and The Institute
for Johns Hopkins
Nursing take
responsibility
for the content,
quality, and
scientific integrity
of this CE activity.
At
the conclusion
of this activity,
participants
should be able
to:
•
Discuss
the recent
contributions
of inflammation
to the pathogenesis
of bronchopulmonary
dysplasia
•
Describe
the fundamental
connection
between
lung development
and bronchopulmonary
dysplasia
•
Identify
the exciting
developments
in the area
of genetic
associations
and bronchopulmonary
dysplasia
Over
the years several
animal models
were developed
to study the pathophysiology
of BPD. Early
models focused
on hyperoxia in
neonatal animals,
as the high levels
of supplemental
oxygen used to
treat babies with
respiratory distress syndrome (RDS) were believed
to be important
in the pathophysiology
of BPD. Fundamental
contributions
originated from
the laboratories
of Drs. Frank,
Massaro, and colleagues.
Today, although
lower FiO2 levels
may be used clinically,
the concept that
even room air
represents "hyperoxia"
to the very immature
lung is consistent
with oxidant injury
being an important
pathophysiologic
factor in BPD
(2). Two large
animal models
of BPD were developed,
in the baboon
(Drs. Coalson,
DeLemos, Yoder,
Seidner and colleagues
(3)), and in the
sheep (Drs. Bland,
Albertine, Carlton,
and colleagues
(4)).
Our first focus
is on inflammation,
including antenatal
inflammation (e.g., chorioamnionitis),
and ongoing postnatal
inflammation,
and inflammation
related to infection.
Drs. Jobe, Ikegami,
Kallapur, Kramer
and colleagues
have made significant
contributions
with their studies
of inflammation
and its effects
on the preterm
lung. Human clinical
studies, such
as that by Viscardi
and colleagues (5),
have also corroborated
the concept that
early inflammation
is an independent
risk factor for
BPD. Multiple
previous studies
found an association
of proinflammatory
cytokines in tracheal
aspirates with
the subsequent
development of
BPD; herein we
discuss a recent
one by Baier and
colleagues. As
we develop better
tools for use
in human infant
samples (for example
real-time PCR
on cell pellets
from tracheal
aspirates, or
proteomics on
small volume samples)
we will be able
to correlate better
the results from
laboratory studies
with those in
babies.
Impairment of
alveolarization,
with fewer and
larger alveoli
present (3, 4,
6-8), is one of
the single most
consistent findings
in all BPD models;
vascular development
is also frequently
impaired as well.
Recent studies
demonstrate support
for impaired regulation
by vascular endothelial growth factor (VEGF) in human
infants with BPD,
and that VEGF
may be able to
improve the impaired
alveolarization
seen in hyperoxia.
Our knowledge
of possible genetic
predispositions
to BPD is also
growing rapidly,
although further
data are needed
to draw definitive
conclusions. Investigators
have focused on
genes related
primarily to inflammation,
and the surfactant
system. Additional
recent developments
in understanding
the evolution
of BPD involve
alterations in
cellular phenotype,
including lipofibroblast
to myofibroblast
(9) and monocyte
to fibrocyte in
other models (10).
The figure below summarizes our concept of the evolution of the relative contributions of different clinical risk factors.
Evolving
Clinical
Risk
Factors
for
Bronchopulmonary
Dysplasia
BPD
remains
a
disease
with
multifactorial
etiology,
with
various
factors
combining
to
"tip
the
scale"
for
a
given
baby
to
develop
BPD.
The
original
clinical
concepts
proposed
by
Northway
associated
BPD
with
high
supplemental
oxygen
and
ventilation
levels,
moderate
prematurity
and
primary
lung
disease
such
as
respiratory
distress
syndrome.
Additional
clinical
studies
suggested
that
other
factors
contribute
such
as
inflammation
/
infection
/
ureaplasma,
patent
ductus
arteriosus,
nutritional
factors
including
vitamin
A
deficiency,
and
possible
genetic
factors.
Over
time
the
clinical
risk
factors
have
changed,
with
respiratory
support
remaining
important,
but
extreme
prematurity
looming
larger
and
primary
lung
disease
playing
less
of
a
role.
The
exposure
of
the
more
premature
lung
has
given
rise
to
the
important
prominence
of
impaired
or
simplified
alveolarization,
along
with
aberrant
vascularization.
In
addition,
the
prominence
of
early
inflammation,
and
in particular,
persistent inflammation,
is
now
well-documented.
Finally, data
are emerging
that support
specific genetic predispositions.
We will focus
our discussion
on recent important
basic science
investigations
and complementary
studies in human
infants to further
our understanding
of the pathogenesis
of BPD. In addition
to working with
good in vitro
and animal models,
we continue to
need solidly designed,
randomized controlled
trials focusing
on the everyday
questions we face
in the NICU: appropriate
targets for pO2
/ oxygen saturation
and carbon dioxide
levels; methods
of supporting
respiration; optimal
nutrition; favorable
environmental
influences; ways
to decrease infection
and to control
inflammation;
etc. As we are
all aware, there
is still much
work to be done
to prevent and
ameliorate this
important disease.
INFLAMMATION
ÖÖ.A MAJOR PLAYER
IN BPD PATHOGENESIS
Baier
RJ, Abdul Majid,
Parupia H, Loggins
J, and Kruger
TE. CC chemokine
concentrations
increase in respiratory
distress syndrome
and correlate
with development
of bronchopulmonary
dysplasia.
Pediatr Pulmonol.2004;
37:137-148. (For
non-journal subscribers,
an additional
fee may apply
for full text
articles)
Young
KC, Del Moral
T, Claure N, Vanbuskirk
S, Bancalari E. The association
between early
tracheal colonization
and bronchopulmonary
dysplasia.
J Perinatol. 2005
Jun;25(6):403-7. (For
non-journal subscribers,
an additional
fee may apply
for full text
articles)
Kallpur
SG, Bachurski
CJ, Le Cras TD,
Joshi SN, Ikegami
Machiko, and Jobe
AH. Vascular
changes after
intra-amniotic
endotoxin in preterm
lamb lungs.
Am J Physiol Cell
Mol Physiol, 2004;
287:1178-1185. (For
non-journal subscribers,
an additional
fee may apply
for full text
articles)
Examining
the role early
inflammation may
play in the pathophysiology
of the disease
Premature infants
are exposed
to systemic
and lung inflammation
in utero
(e.g., chorioamnionitis,
ureaplasma),
and postnatally
during times
of infection
and systemic
illness. A number
of studies have
examined the
role of early
inflammation
by measuring
proinflammatory
cytokines in
tracheal aspirates
and there is
evidence that
inflammation
and tracheal
elevations in
proinflammatory
cytokines are
associated with
future and concurrent
BPD. Earlier
studies of the
role of cytokines
in BPD focused
on the role
of proinflammatory
cytokines including
interleukin-1ß
(IL-1ß),
tumor necrosis
factor α (TNF-α)
and IL-6, and
the neutrophil
chemotactic
chemokine, IL-8.
Neutrophil influx
into the lung
occurs early
in respiratory
distress syndrome
(RDS). However
the alveolar
macrophage plays
a central role
shortly thereafter
in RDS, as well
as in animal
models of lung
fibrosis.
Migration to
the lung and
activation of
macrophages
is mediated
largely through
the action of
proinflammatory
cytokines called
CC chemokines
(chemotactic
cytokines).
Chemokines are
classified into
4 families
(C, CC, CXC,
and CX3C) according
to the number
and spacing
of cysteine
residues. Baier
et al. studied
whether CC chemokine
family members
increase in
the tracheal
aspirates obtained
from mechanically
ventilated preterm
infants during
the first 3
weeks of life.
The study population
consisted of
56 preterm babies
with birth weight
<1500 g,
who were mechanically
ventilated,
had a radiologic
diagnosis of
RDS, and survived
to 28 days.
Serial tracheal
aspirates (TA)
were obtained
daily for the
first 21 days
of life for
as long as the
infant remained
on mechanical
ventilation.
The concentrations
of different
CC chemokines
were measured
using ELISA
assays, and
normalized to
the secretory
component of
IgA. Routine
bacterial cultures
were performed
on tracheal
aspirates collected
in the first
24h. Cultures
for both mycoplasma
huminis (Mh)
and ureaplasma
urealyticum
(Uu) were performed
on admission
and repeated
two times during
the first week
of life if the
infant remained
intubated. Placental
inflammation
was considered
present if the
pathologist's
report indicated
the presence
of histologic
inflammation
of fetal membranes.
The mean gestational
age and birth
weight of the
study population
were 26.8 weeks
and 917g. TA
cultures obtained
during the first
few days of
life grew Uu
on at least
one occasion
from 23 (41%)
and Mh from
3 (5%) infants.
Thirty of 56
(54%) infants
studied were
oxygen dependent
at 28 days ("BPD28"),
and 14 (25%)
were oxygen
dependent at
36 weeks corrected
gestational
age ("BPD36").
Oxygen dependent
infants were
smaller and
of lower gestational
age, were more
often treated
with postnatal
steroids, and
were more likely
to have pulmonary
hemorrhage.
BPD28 infants
were more likely
to have a TA
culture positive
for Uu (but
not BPD36 infants).
TA concentrations
of most CC chemokines
increased significantly
over time during
the course of
RDS, although
the pattern
varied for different
chemokines.
Early on, CC
chemokine concentrations
were similar
in BPD and non-BPD
infants, but
there was a
greater subsequent
rise in levels
in BPD28 infants.
The maximum
TA CC chemokine
level for each
chemokine studied
was associated
with BPD28,
and maximal
TA concentrations
of all chemokines
studied were
also higher
in BPD36 infants
although only
two were statistically
significant.
This study demonstrates
that increased
production of
CC chemokines
is associated
with later BPD
suggesting that
this family
of chemokines,
in addition
to previously
described inflammatory
mediators, may
play an important
role in the
development
of BPD in premature
newborns.
Young and colleagues
studied 308
infants with
birth weight
500 to 1000
grams who were
intubated by
day 1 to examine
the correlations
among chorioamnionitis,
initial tracheal
aspirate culture
results and
BPD (oxygen
requirement
at 28 days,
"BPD28," and
at 36 weeks
gestation, "BPD36").
They found that
there was an
association
between chorioamnionitis
and both BPD28
(p=0.05) and
BPD36 (p=0.008).
The infants
who had chorioamnionitis
were significantly
more likely
to have a positive
initial tracheal
culture, although
the association
between a positive
initial tracheal
culture and
BPD did not
reach statistical
significance.
However, this
association
was highly significant
in the subgroup
of infants born
at 700-1000g,
with 61% of
initial tracheal
culture positive
infants going
on to develop
BPD28 compared
to 39% of non-colonized
infants. Again,
this study adds
credence to
the concept
of early inflammation
being a "setup"
for BPD.
Kallapur
et al addressed
this important
question: does
exposure to
antenatal inflammation
alone, without
exposure to
mechanical ventilation
or oxygen toxicity,
cause pulmonary
vascular changes
and remodeling
similar to that
seen in BPD?
This would add
another mechanism
by which inflammation
contributes
to the development
of BPD. The
authors hypothesized
that intraamniotic
(IA) endotoxin
would inhibit
expression of
proteins critical
for endothelial
function followed
by vascular
remodeling in
preterm lung.
Pregnant ewes
at 118 days
gestation (term
150 days) were
given IA injections
of saline (control)
or endotoxin,
and preterm
lambs delivered
at 119-125 days
gestation. mRNA
and / or protein
levels for molecules
important in
vascular development,
including VEGF,
PECAM-1 (platelet
endothelial
cell adhesion
molecule-1)
and endothelial
NOS (nitric
oxide synthase)
were determined.
Vascular morphology,
including measurements
of arteriolar
wall thickness,
thickness of
muscularis media,
area of smooth
muscle, and
adventitial
fibrosis with
quantitative
scoring were
performed.
The cord blood
hematocrit,
pO2, pCO2, and
pH were similar
between control
and endotoxin-exposed
preterm lambs.
Whole lung e-NOS
protein was
decreased after
intra-amniotic
endotoxin with
a maximum decrease
at day 4 and
e-NOS expression
appeared to
be selectively
reduced in the
small pulmonary
arteries compared
with large conducting
vessels. IA
endotoxin also
decreased VEGF
mRNA and protein,
as well as PECAM-1
and receptors
for VEGF and
other angiogenic
factors. Increased
arteriolar smooth
muscle thickness,
along with increased
adventitial
layer fibrosis
and cellularity,
were also observed
after endotoxin
injection. These
data support
the hypothesis
that antenatal
inflammation
alone decreases
vascular-related
proteins. The
vascular changes
induced by fetal
lung inflammation
may contribute
to decreased
alveolarization.
This study offers
one possible
mechanism to
explain the
association
between antenatal
inflammation
(chorioamnionitis)
and BPD observed
in clinical
studies.
THE
ALVEOLAR-CAPILLARY
UNIT Ö WHAT HAPPENS
IN BPD?
Bhatt
AJ, Pryhuber GS,
Huyck H, Watkins
RH, Metlay LA,
and Maniscalco
WM Disrupted
pulmonary vasculature
and decreased
vascular endothelial
growth factor,
Flt-1, and TIE-2
in human infants
dying with bronchopulmonary
dysplasia.
Am J Respir Crit
Care Med 2001,
164:1971-1980. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Van
Tuyl M, Liu J,
wang J, Kuliszewski
M, Tibboel D,
and Post M. Role of
oxygen and vascular
development in
epithelial branching
morphogenesis
of the developing
mouse lung.
Am J Physiol Cell
Mol Physiol 2005,
288:L167-L178. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Kunig
AM, Balasubramaniam
V, Markham NE,
Morgan D, Montgomery
G, Grover TR,
Abman SH. Recombinant
human VEGF treatment
enhances alveolarization
after hyperoxic
lung injury in
neonatal rats.
Am J Physiol Lung
Cell Molec Biol,
in press. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Thebaud
B, Ladha F, Michelakis
E, Moudgil R,
Dyck J, Eaton
F, Hashimoto K,
Harry G, Archer
SL. VEGF gene
therapy increases
survival, promotes
lung angiogenesis
and prevents alveolar
damage in hyperoxia-induced
lung injury: Evidence
that angiogenesis
participates in
alveolarization.
Circulation, in
press. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Studying
the associated
vascular abnormalities
seen in impaired
alveolarization
Impaired alveolarization
and capillary
development
are hallmarks
of BPD. Although
there have been
many significant
studies with
a focus on impaired
alveolarization,
more attention
has recently
been paid to
the associated
abnormalities
seen in the
vasculature.
Bhatt et al
studied autopsied
human infant
lung for a marker
of endothelial
cells (platelet
endothelial
cell adhesion
molecule-1,
PECAM-1), and
for VEGF and
its receptors.
The objective
was to demonstrate
the relationship
between abnormal
vascularization
and possible
abnormal expression
of angiogenic
growth factors
or their receptors
in the setting
of chronic lung
disease in premature
infants. Lung
samples were
obtained at
autopsy from
infants with
BPD (n = 5)
and from "control"
term or near
term patients
dying without
lung disease
(n = 5).
The patients
with no lung
disease (NLD
group) were
significantly
more mature
at birth than
the BPD group.
While the chronologic
age at death
was significantly
greater in the
BPD group, there
was no difference
in the post
conceptional
age at death,
suggesting that
the potential
lung developmental
stages at death
were similar.
Compared with
infants in the
NLD group, babies
with BPD had
decreased PECAM-1
immunostaining
and the alveolar
capillaries
were frequently
noted in thickened
alveolar septa.
PECAM-1 protein
and mRNA in
whole lung were
significantly
decreased in
the BPD group
compared to
NLD group, suggesting
a possible decrease
in the relative
number of endothelial
cells in the
patients with
BPD. Furthermore,
the mRNAs for
the angiogenic
growth factor
VEGF and its
receptor were
also decreased
in BPD patients.
This study suggests
that infants
dying with BPD
may have disrupted
alveolar vascular
development,
and that these
abnormalities
may result from
impaired expression
of VEGF and
angiogenic endothelial
receptors.
The work of
Van Tuyl
et al adds
additional insight
to the understanding
of the epithelial-vascular
interaction
and the importance
of the fetal
hypoxic state
for lung development.
In their elegant
experiments,
they used genetically
engineered mice
that expressed
a "reporter"
gene exclusively
in either endothelial
or epithelial
cells, such
that cells expressing
the reporter
gene could be
analyzed by
specific staining.
Explants of
embryonic lungs
were maintained
in an atmosphere
of either 3%
O2
or 20% O2
and the
production of
hypoxia-inducible
factor (HIF-1α),
an important
regulator of VEGF,
and VEGF itself
were also able
to be blocked.
In this lung
explant model,
exposure to
low oxygen (3%
O2) enhanced
both epithelial
branching morphogenesis
and vascular
development
compared to
20% O2, with
more complex
epithelial and
vascular branching.
Explants cultured
in 3% O2 also
had increased
expression of
a specific marker
for alveolar
type II cells,
suggesting maintenance
of appropriate
epithelial differentiation.
The increase
in vascularization
in explants
cultured at
3% was associated
with greater
PECAM-1 expression,
again confirming
that low oxygen
stimulates vascular
development
in embryonic
lung explants.
VEGF mRNA was
also dramatically
increased in
explants exposed
to 3% O2. Critical
to the discussion
of impaired
alveolarization
being associated
with impaired
vascularization,
blockage of
HIF-1α as well
as VEGF production
resulted in
a marked decrease
in vascular
development
in the explants
with large areas
devoid of vessels
and this was
accompanied
by decreased
branching morphogenesis.
This effect
was significantly
ameliorated
by addition
of recombinant
VEGF to lung
explant cultures.
Finally, blockage
of VEGF production
was associated
with complete
abrogation of
epithelial branching
morphogenesis
in explants
exposed to 20%
O2, although
the effect was
less in explants
exposed to 3%
O2. This study
lends credence
to the current
concept that
even room air
(21% O2) is
likely toxic
to the developing
lung and that
this "relative
hyperoxia" inhibits
both pulmonary
vascular development
and epithelial
branching morphogenesis,
suggesting caution
should be used
in determining
appropriate
saturation targets
for premature
infants.
Two exciting
studies specifically
examining the
effect of VEGF
on alveolarization
are "in press."
Kunig et
al exposed
two day old
rat pups to
75% O2 or room
air for 12 days.
Both groups
were then exposed
to room air,
and treated
with a form
of VEGF or normal
saline from
days 14 to 22.
Careful morphometric
analysis demonstrated
that hyperoxia
resulted in
findings of
decreased alveolarization
and vessel density,
despite an 8
day recovery
period in room
air. VEGF treatment
after hyperoxia
ameliorated
these findings.
The results
caused the authors
to speculate
that "persistent
abnormalities
of lung structure
after hyperoxia
may be partly
due to impaired
VEGF signaling."
Thebaud
et al exposed
neonatal rats
to 95% O2 from
birth (PAS meeting 2004). The VEGF
receptor was
blocked by subcutaneous
injection of
a VEGF trap
at day 4, 7
and 10. At 15
days, morphometric
studies demonstrated
that VEGF-trap
decreased lung
VEGF and VEGF
receptor 2 and
led to enlargement
of the air spaces
and loss of
lung capillaries,
mimicking BPD.
In hyperoxia-exposed
rats there was
air space enlargement
and loss of
lung capillaries,
associated with
decreased lung
VEGF and VEGFR-2.
In vivo intratracheal
gene transfer
of a form of
VEGF at day
4 using a viral
vector increased
lung capillary
growth and improved
alveolarization.
Again, these
authors suggest
that "VEGF-driven
angiogenesis
promotes alveolar
development."
These elegant
studies are
generating ideas
for the next
generation of
treatment and
prevention of
BPD.
"HIGH
RISK TO DEVELOP
SEVERE BPD" --
CAN WE TELL FROM
THE GENETIC MAP?
Kazzi
SN, Kim UO, Queasney
MW, and Buhimschi
I. Polymorphism
of tumor necrosis
factor and risk
and severity of
bronchopulmonary
dysplasia among
very low birth
weight infants.
Pediatrics. 2004;
114(2). (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Rova
M, Haataja R,
Marttila R, Ollikainen
V, Tammela O,
and Hallman M. Data mining
and multiparameter
analysis of lung
surfactant protein
genes in bronchopulmonary
dysplasia.
Hum Mol Genet.2004;13:
1095-1104. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Haataja
R, Rova M, Marttila
R, Hallman M,
Oulu, Seinajoki. TDT analysis
of surfactant
protein B gene
intron 4 deletion
variants in Finnish
infants with Bronchopulmonary
dysplasia.
Proc Am Thoracic
Soc 2005; 2: A24. (For
non-journal subscribers,
an additional
fee may apply
for full text
article)
Reporting
on new developments
on the role of
genetic factors
in the pathophysiology
of BPD
Certain infants
develop severe
BPD despite
exposure to
the same clinical
risk factors
and treatments
as infants who
do not develop
BPD. The role
of genetic factors
in the development
of this disease
is emerging.
Inflammation
plays an important
role in the
pathogenesis
of BPD, and
one of the earliest
proinflammatory
cytokines produced
during an inflammatory
response is
tumor necrosis
factor-α (TNF-α).
TNF-α triggers
the release
of secondary
mediators of
inflammation,
such as interleukin-1
and interleukin-6,
as well as of
itself. Frequently
occurring DNA
sequence variants
(polymorphisms)
within the TNF-α
gene have been
identified,
and several
have been associated
with increased
levels of TNF-α.
The objective
of the study
by Kazzi et
al was to examine
the effect of
three such polymorphisms
involving the
presence of
either adenine
(A) or guanine
(G) in the TNF-α
(TNF-α-238,
TNF-α-308) or
TNF-ß (LT-α+250,
also known as
lympotoxin,
LT) genes on
the development
and severity
of BPD among
very low birth
weight (VLBW)
infants.
Preterm infants
with a birth
weight of ≤1250
g were genotyped
for the TNF
polymorphisms.
Other variables
examined included
gestational
age, severity
of respiratory
illness at the
time of entry
into the study,
diagnosis of
patent ductus
arteriosus,
pneumonia, late
onset sepsis,
and necrotizing
enterocolitis.
The definition
and severity
of BPD among
surviving infants
were as described
by Jobe and
Bancalari: oxygen
therapy used
for at least
28 days and
severity based
on status at
36 weeks or
at discharge,
whichever came
first: 1) mild
BPD: infant
breathing room
air at 36 weeks;
2) moderate
BPD: infant
requiring <
30% oxygen at
36 weeks; 3)
severe BPD:
infant required
> 30% supplemental
oxygen and/or
positive pressure
therapy at 36
weeks.
A total of
154 infants
were enrolled;
120 infants
survived to
36 weeks gestational
age. Infants
who developed
BPD had a lower
birth weight
and younger
gestational
age, were likely
to have been
exposed to prenatal
corticosteroids,
to have prolonged
rupture of fetal
membranes (>18h),
and to have
an Apgar score
at 5 minutes
of ≤ 5. In this
population,
there were no
associations
between BPD
and the alleles
LT-α+250 or
TNF-α-308. However,
infants with
BPD were significantly
less likely
to carry the
TNF-α-238 AA
or GA genotype,
compared with
infants without
BPD. None of
the infants
with BPD carried
the TNF-α-238
AA genotype,
compared with
3% of infants
without BPD,
and only 2%
of infants with
BPD carried
the GA TNF-α-238
genotype, compared
with 14% of
infants without
BPD. Examining
the severity
of BPD, none
of the infants
with moderate
or severe BPD
carried the
TNF-α-238 AA
genotype, compared
with 8% of infants
with mild BPD.
The TNF-α-238
GA genotype
was absent among
infants with
severe BPD and
was observed
in 5% of the
infants with
moderate BPD,
compared with
21% of infants
with mild BPD.
Multivariate
logistic regression
analysis demonstrated
significant
contributions
of pneumonia
and the absence
of the adenine
allele of TNF-α-238
to the development
of BPD. These
findings suggest
that the presence
of the adenine
allele of TNF-α-238
among VLBW infants
may confer a
protective effect
against the
development
of BPD.
Rova et
al examined
the relationship
between surfactant
protein genotyping
and the development
of BPD. BPD
is often preceded
by RDS, which
is due primarily
to deficiency
of pulmonary
surfactant at
birth. Surfactant
components are
also involved
in immunity
and may serve
as anti-inflammatory
factors. In
this study all
surfactant associated
protein genes
(SP-A1, SP-A2,
SP-B, SP-C,
and SP-D) were
examined as
potential susceptibility
factors in the
etiology of
BPD.
The study population
consisted of
365 infants
born between
24 and 32 weeks
of gestation.
The diagnostic
criterion for
BPD was the
continuous requirement
for supplemental
oxygen at postmenstrual
age 36 weeks
or at 56 days
of age for those
born at ≥32
weeks; 86 infants
with BPD and
279 control
infants were
included. Controls
were further
subdivided into
two groups:
188 infants
were RDS-positive
and 91 infants
had neither
BPD nor RDS.
Genotyping for
SP-A1, SP-A2,
SP-B, SP-C,
and SP-D was
performed and
allele frequencies
were calculated.
The frequency
of a specific
SP-B gene variant
involving a
small deletion
in intron 4
was significantly
increased in
infants with
BPD (P = 0.008).
No association
between this
SP-B variant
and RDS was
found. Low birth
weight (<1050
g) together
with the presence
of the SP-B
intron 4 deletion
variant allele
predicted BPD
in 22 of 24
cases. Logistic
regression analysis
demonstrated
that the presence
of one or two
SP-B intron
4 deletion variant
alleles was
independently
associated with
BPD.
The same group
of investigators
(Hataaja et
al) presented
a corroborating
study at the
American Thoracic
Society meeting
in May 2005
utilizing the
Transmission
disequilibrium
test (TDT) to
evaluate the
familial segregation
of SP-B intron
4 alleles from
parents to affected
offspring. Eighty-seven
Finnish father-mother-offspring
trios with an
affected baby
of <32 weeks
of gestation
were included
in the analysis.
BPD was defined
as the need
for supplemental
oxygen at least
28 days after
birth. The SP-B
intron 4 deletion
variant allele
frequency was
significantly
higher in the
affected infants
compared to
the frequency
of parental
non-transmitted
alleles (P =
0.025). The
deletion variant
allele showed
significantly
increased transmission
to affected
offspring, compared
to the other
SP-B intron
4 alleles. There
was no paternal
or maternal
preference in
transmission
of the risk
allele. These
results support
the previous
finding of this
SP-B intron
4 deletion variant
as a risk factor
predisposing
to BPD. Genotypic
analysis of
VLBW infants
at risk of developing
BPD may provide
clinicians with
a useful tool
of targeting
preventative
therapies in
the future.
Accreditation
· back
to top Physicians
This
activity has been
planned and implemented
in accordance
with the Essential
Areas and policies
of the Accreditation
Council for Continuing
Medical Education
through the joint
sponsorship of
The Johns Hopkins
University School
of Medicine and
The Institute
for Johns Hopkins
Nursing. The Johns
Hopkins University
School of Medicine
is accredited
by the ACCME to
provide continuing
medical education
for physicians.
Nurses
The
Institute for
Johns Hopkins
Nursing is accredited
as a provider
of continuing
education in nursing
by the American
Nurses Credentialing
Center's Commission
on Accreditation.
Credit
Designations ·
back
to top Physicians
The
Johns Hopkins
University School
of Medicine designates
this educational
activity for a
maximum of 0.5
category 1 credits
toward the AMA
Physician's Recognition
Award. Each physician
should claim only
those credits
that he/she actually
spent in the activity.
Nurses
The
Institute for
Johns Hopkins
Nursing designates
this activity
for a maximum
of 0.5 contact
hours for this
eNewsletter.
Respiratory
Therapists
Contact
your state licensing
board to confirm
that AMA PRA category
1 credits are
accepted toward
fulfillment of
RT requirements.
Target
Audience ·
back
to top This
activity has been
developed for
Neonatologists,
NICU Nurses and
Respiratory Therapists
working with Neonatal
patients. There
are no fees or
prerequisites
for this activity.
Learning
Objectives ·
back
to top The
Johns Hopkins
University School
of Medicine and
The Institute
for Johns Hopkins
Nursing take responsibility
for the content,
quality, and scientific
integrity of this
CE activity. At
the conclusion
of this activity,
participants should
be able to:
•
Discuss the
recent contributions
of inflammation
to the pathogenesis
of bronchopulmonary
dysplasia
•
Describe the
fundamental
connection
between lung
development
and bronchopulmonary
dysplasia
•
Identify the
exciting developments
in the area
of genetic
associations
and bronchopulmonary
dysplasia
Faculty
Disclosure Policy
Affecting CE Activities
· back
to top As
providers accredited
by the Accreditation
Council for Continuing
Medical Education
and American Nursing
Credentialing
Center, it is
the policy of
The Johns Hopkins
University School
of Medicine and
The Institute
of Johns Hopkins
Nursing to require
the disclosure
of the existence
of any significant
financial interest
or any other relationship
a faculty member
or a provider
has with the manufacturer(s)
of any commercial
product(s) discussed
in an education
presentation.
The presenting
faculty reported
the following:
•
Dr. Nogee
has indicated
a financial
relationship
of grant/research
support with
Forest Laboratories
and has received
an honorarium
from Forest
Laboratories.
•
Dr. Lawson
has indicated
a financial
relationship
of grant/research
support from
the NIH. He
also receives
financial/material
support from
Nature Publishing
Group as the
Editor of
the Journal
of Perinatology.
All
other faculty
have indicated
that they have
not received financial
support for consultation,
research, or evaluation,
nor have financial
interests relevant
to this e-Newsletter.
Unlabelled/Unapproved
Uses ·
back
to top No
faculty member
has indicated
that their presentation
will include information
on off label products.
Internet
CE Policy ·
back
to top The
Offices of Continuing
Education (CE)
at The Johns Hopkins
University School
of Medicine and
The Institute
for Johns Hopkins
Nursing are committed
to protect the
privacy of its
members and customers.
The Johns Hopkins
University maintains
its Internet site
as an information
resource and service
for physicians,
other health professionals
and the public.
The
Johns Hopkins
University School
of Medicine and
The Institute
For Johns Hopkins
Nursing will keep
your personal
and credit information
confidential when
you participate
in a CE Internet
based program.
Your information
will never be
given to anyone
outside The Johns
Hopkins University
program. CE collects
only the information
necessary to provide
you with the service
you request.